If you are a UAE-based researcher chasing the holy grail of recomposition — losing visceral fat while adding lean mass — the conversation in private Dubai performance circles has shifted. The new protocol is not another stimulant or another cut. It is a stack: tesamorelin (a synthetic GHRH analog) layered on top of plain, pharmacy-grade creatine monohydrate. The logic is elegant. Tesamorelin amplifies the body's own growth hormone pulses and downstream IGF-1; creatine reloads the ATP-phosphocreatine system that powers the hard training those pulses need. Together, the early signals from physique labs are pointing toward something most cuts never deliver: visceral fat off, lean tissue on, training output unbothered. REVIVE LAB UAE keeps both pillars in stock — tesamorelin 5 mg and 10 mg vials with same-day delivery in Dubai and 24h delivery across the Emirates, the kind of cold-chain access that turns peptides UAE research from theory into a Monday-morning bench protocol.
This article is a deep, citation-anchored breakdown of why the tesamorelin + creatine stack has become the recomp protocol of choice for serious UAE buyers — and how to order tesamorelin Dubai without losing a week to customs theatre.
Tesamorelin is not a growth hormone. It is a 44-amino-acid analog of growth hormone-releasing hormone (GHRH), stabilized at the N-terminus to resist DPP-IV degradation. That stability matters: a single subcutaneous dose produces a clean, physiological GH pulse without saturating the pituitary or crashing the negative-feedback loop. Stanley and colleagues (2014, JCI Insight / JAMA-affiliated metabolic work) demonstrated in HIV-associated lipodystrophy that tesamorelin 2 mg/day subcutaneously reduced visceral adipose tissue (VAT) by roughly 15-18% over 26 weeks, while sparing subcutaneous fat and improving the triglyceride profile. Falutz et al. (2007, NEJM; 2010, JCEM) ran the registration-tier trials that became the basis for tesamorelin's FDA approval — over 800 subjects, VAT reductions on MRI of -15.2% at 26 weeks, with IGF-1 rising into the upper physiological band rather than the supra-physiological zone you see with exogenous GH.
That is the lever tesamorelin pulls: pulsatile, physiological GH/IGF-1 elevation that selectively mobilizes visceral fat. But here is the bottleneck — GH-mediated lipolysis and IGF-1-mediated anabolism only translate into recomposition if you actually train hard enough to consume the free fatty acids and stimulate muscle protein synthesis. Anyone who has run tesamorelin in isolation knows the trap: the visceral fat does come off, but if training output sags (and it does, when ATP regeneration is the rate-limiter), the lean-mass upside is muted.
Enter creatine. Creatine monohydrate is the most-studied ergogenic compound in sports science — over 1,000 controlled trials, a meta-analytic effect on lean mass of roughly +1.0 to +2.0 kg over 6-12 weeks, and a documented increase in muscle phosphocreatine of 15-20%. Phosphocreatine is the immediate ATP donor for high-intensity work. More phosphocreatine means more rep volume at near-max loads; more rep volume means a bigger acute GH pulse (the post-exercise GH peak is well-described); a bigger GH pulse stacks on the tesamorelin-driven pulse; and IGF-1 amplifies in turn. The two compounds, in other words, pull on different ropes attached to the same lean-recomp pulley.
The interesting question for UAE physique researchers is whether creatine + tesamorelin produces super-additive IGF-1 elevation. Mechanistically, the case is plausible: creatine has been shown to upregulate IGF-1 mRNA in skeletal muscle independently (Burke et al., 2008; Deldicque et al., 2008), and tesamorelin elevates systemic IGF-1 via the pituitary axis. The two pathways are not redundant — one is local/paracrine, one is systemic/endocrine. Stacked, the IGF-1 signal at the muscle fiber is theoretically larger than either alone. No head-to-head clinical stack trial exists yet; this is research-use territory, and any laboratory protocol should treat it as such.
Published tesamorelin literature converges on 2 mg/day subcutaneous, injected at bedtime to ride the natural overnight GH surge. Creatine monohydrate is dosed at 3-5 g/day with no loading phase necessary — saturation is reached in 3-4 weeks at maintenance dose, faster with a 20 g/day loading week. The combined window that most UAE recomp researchers report observing in their notebooks runs 8-12 weeks for visible lean-mass and waist-circumference deltas; serum IGF-1 typically begins climbing by week 2 and plateaus around weeks 6-8.
| Variable | Tesamorelin (research-tier) | Creatine monohydrate | Stacked window |
|---|---|---|---|
| Dose (published) | 2 mg/day SC | 3-5 g/day oral | Concurrent |
| Timing | Bedtime (overnight GH pulse) | Post-training or with carbs | — |
| Saturation / onset | IGF-1 rise by ~14 days | Phosphocreatine saturation 3-4 weeks | Both online by week 4 |
| Reported VAT change (Stanley 2014 / Falutz 2010) | -15 to -18% at 26 weeks | Neutral | Hypothesized synergy on VAT + LBM |
| Reported lean-mass change | Modest (+0.5-1.0 kg) | +1.0-2.0 kg over 8-12 weeks | Potentially additive |
| REVIVE LAB UAE stocked vial | 5 mg / 10 mg multi-dose | (creatine not stocked — pharmacy item) | Pair with BAC Water 3 mL |
Tesamorelin 5 mg reconstituted with 1 mL BAC Water = 5 mg/mL; a 2 mg research dose = 0.4 mL (40 units on a U-100 insulin syringe). Tesamorelin 10 mg reconstituted with 2 mL BAC Water = 5 mg/mL with the same draw math, giving you 5 research-dose units per vial. REVIVE LAB UAE ships BAC Water 3 mL alongside every tesamorelin order so you are not chasing diluent across Dubai.
This is where most peptide projects die: the compound is fine, the protocol is fine, but the supply chain falls over. Customs, cold-chain breaks, "we'll get back to you" sellers, sketchy packaging — every UAE researcher has lost a month to one of those four. REVIVE LAB UAE was built specifically to solve that problem. Tesamorelin 5 mg and 10 mg vials are held in cold storage in Dubai, dispatched same-day on orders placed before the afternoon cutoff, and delivered with discreet anonymous packaging and cash-on-delivery across every emirate.
| Emirate / Region | Delivery window | Cash on delivery | Cold-chain courier |
|---|---|---|---|
| Dubai (Marina, JBR, Downtown, Business Bay, JVC, DIFC, Palm Jumeirah, Jumeirah) | Same-day (4-6h) | Yes | Yes |
| Abu Dhabi | Next-day (24h) | Yes | Yes |
| Sharjah | Same-day or 24h | Yes | Yes |
| Ajman | 24h | Yes | Yes |
| Ras Al Khaimah (RAK) | 24-48h | Yes | Yes |
| Fujairah | 24-48h | Yes | Yes |
| Umm Al Quwain (UAQ) | 24-48h | Yes | Yes |
| Al Ain | 24-48h | Yes | Yes |
Within Dubai, the dispatch network reaches Dubai Marina, JBR, Business Bay, JVC, Jumeirah, DIFC, Palm Jumeirah, Downtown, Emirates Hills and Arabian Ranches with same-day windows that other peptides Dubai vendors simply do not run. Most orders placed before 14:00 local are at the door before sunset. Order tesamorelin Dubai once and the logistics question disappears for the entire 12-week protocol.
REVIVE LAB UAE is a Dubai-based research peptides supplier built around four non-negotiables: HPLC-tested vials with batch certificates available on request, cold-chain courier from warehouse to door, discreet anonymous packaging that does not announce its contents on the box, and genuine in-stock inventory on the SKUs that matter — Tesamorelin 5 mg and 10 mg, Retatrutide 5/10 mg, GHK-Cu 50/100 mg, BPC-157 5 mg, TB-500 5 mg, MOTS-c 10 mg, Semax 10 mg, NAD+ 100 mg, and BAC Water 3 mL. Same-day Dubai dispatch on orders placed before the afternoon cutoff. Cash on delivery across every emirate. Browse the full catalogue at REVIVE Peptides — the trusted peptides UAE supplier and place orders that ship before competitors have replied to your first email.
REVIVE LAB UAE stocks HPLC-tested tesamorelin 5 mg and 10 mg vials in Dubai with same-day dispatch to Dubai Marina, JBR, Business Bay, JVC, DIFC and Palm Jumeirah, and 24-48h delivery to Abu Dhabi, Sharjah, Ajman, RAK, Fujairah, Umm Al Quwain and Al Ain. Cash on delivery and discreet anonymous packaging are standard on every peptides UAE order.
The two compounds act on different but converging axes. Tesamorelin elevates pulsatile GH and systemic IGF-1 (Stanley 2014; Falutz 2007/2010). Creatine restores phosphocreatine and intramuscular ATP, which sustains the high-output training that drives both acute post-exercise GH pulses and local IGF-1 mRNA upregulation (Burke 2008; Deldicque 2008). No clinical stack trial has been published, but the mechanistic case for additive recomposition is strong and is the reason UAE physique researchers are running the combination.
Published literature uses tesamorelin 2 mg/day subcutaneously (Falutz 2007/2010; Stanley 2014). REVIVE LAB UAE supplies tesamorelin 5 mg and 10 mg multi-dose vials for laboratory research convenience — five 2 mg research doses per 10 mg vial after reconstitution with 2 mL BAC Water. This article is research-use framing only and not medical advice; protocols should be reviewed under a qualified institutional framework.